Dexamphetamine-induced reduction of P3a and P3b in healthy participants

Journal of Psychopharmacology

Volumn 25, Issue 12, 2011, Pages 1623-1631

  Albrecht, Matthew A ^a,b   Martin Iverson, Mathew T ^a,b   Price, Greg ^b,c   Lee, Joseph ^b,c   Iyyalol, Rajan ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b GRAYLANDS HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Amphetamine; attention; dopamine; noradrenaline; P300; P3a; P3b; working memory

Indexed keywords

DEXAMPHETAMINE;

ADULT; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EVENT RELATED POTENTIAL; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STIMULUS RESPONSE; SYSTOLIC BLOOD PRESSURE; TASK PERFORMANCE; VISUAL STIMULATION; WORKING MEMORY;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; DEXTROAMPHETAMINE; DOPAMINE; DOUBLE-BLIND METHOD; EVENT-RELATED POTENTIALS, P300; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; REACTION TIME; SCHIZOPHRENIA;

EID: 84863044656     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110376686     Document Type: Article

References (97)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. American J Psychiatry. 1998 ; 155: 761-767 (Pubitemid 28252654)
2. Alain C, Bernstein LJ, Cortese F, Yu H, Zipursky R. Deficits in automatically detecting changes in conjunction of auditory features in patients with schizophrenia. Psychophysiology. 2002 ; 39: 599-606 (Pubitemid 35006907)
3. Angrist B, Gershon S. The phenomenology of experimentally induced amphetamine psychosis. Biol Psychiatry. 1970 ; 2: 95-107
4. Antal A, Kéri S, Bodis-Wollner I. Dopamine D2 receptor blockade alters the primary and cognitive components of visual evoked potentials in the monkey, Macaca fascicularis. Neurosci Lett. 1997 ; 232: 179-181 (Pubitemid 27394860)
5. Antolin T, Berman SM, Conner BT, Ozkaragoz TZ, Sheen CL, Ritchie TL, et al. D2 dopamine receptor (DRD2) gene, P300, and personality in children of alcoholics. Psychiatry Res. 2009 ; 166: 91-101
6. Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of 'representational knowledge': a rational bridge between genetics and the symptoms of mental illness. Cerebr Cortex. 2007 ; 17: i6 - i15
7. Berman SM, Noble EP, Antolin T, Sheen C, Conner BT, Ritchie T. P300 development during adolescence: effects of DRD2 genotype. Clin Neurophysiol. 2006 ; 117: 649-659 (Pubitemid 43343998)
8. Birkas E, Horváth J, Lakatos K, Nemoda Z, Sasvari-Szekely M, Winkler I, et al. Association between dopamine D4 receptor (DRD4) gene polymorphisms and novelty-elicited auditory event-related potentials in preschool children. Brain Res. 2006 ; 1103: 150-158 (Pubitemid 44096934)
9. Blackwood DH, Whalley LJ, Christie JE, Blackburn IM, St Clair DM, McInnes A. Changes in auditory P3 event-related potential in schizophrenia and depression. Br J Psychiatry. 1987 ; 150 (2). 154-160 (Pubitemid 17010728)
10. Bracha HS, Wolkowitz OM, Lohr JB, Karson CW, Bigelow LB. High prevalence of visual hallucinations in research subjects with chronic schizophrenia. Am J Psychiatry. 1989 ; 146 (4). 526-528 (Pubitemid 19099307)
11. Bramon E, McDonald C, Croft RJ, Landau S, Filbey F, Gruzelier JH, et al. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. NeuroImage. 2005 ; 27: 960-968 (Pubitemid 41319709)
12. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. 2004 ; 70 (2-3). 315-329 (Pubitemid 39141109)
13. Bramon E, Shaikh M, Broome M, Lappin J, Bergé D, Day F, et al. Abnormal P300 in people with high risk of developing psychosis. NeuroImage. 2008 ; 41: 553-560
14. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA. 1997 ; 94: 2569-2574 (Pubitemid 27136916)
15. Brown KJ, Gonsalvez CJ, Harris AW, Williams LM, Gordon E. Target and non-target ERP disturbances in first episode vs. chronic schizophrenia. Clin Neurophysiol. 2002 ; 113: 1754-1763 (Pubitemid 35335464)
16. Comerchero MD, Polich J. P3a and P3b from typical auditory and visual stimuli. Clin Neurophysiol. 1999 ; 110: 24-30 (Pubitemid 29210275)
17. Cornil CA, Balthazart J, Motte P, Massotte L, Seutin V. Dopamine activates noradrenergic receptors in the preoptic area. J Neurosci. 2002 ; 22: 9320-9330 (Pubitemid 35356175)
18. Damasio AR, Lobo-Antunes J, Macedo C. Psychiatric aspects in Parkinsonism treated with L-dopa. J Neurol, Neurosurg Psychiatry. 1971 ; 34: 502-507
19. Demiralp T, Cçok A, Devrim M, Isoglu-Alkaç C, Tecer A, Polich J. N2 and P3 components of event-related potential in first-episode schizophrenic patients: scalp topography, medication, and latency effects. Psychiatry Res. 2002 ; 111: 167-179
20. Devrim-Cçok M, Yasemin Keskin-Ergen H, Cçok A. Novelty P3 and P3b in first-episode schizophrenia and chronic schizophrenia. Progr Neuro-Psychopharmacol Biol Psychiatry. 2006 ; 30: 1426-1434
21. Donchin E, Coles MGH. Is the P300 component a manifestation of context updating?. Behavior Brain Sci. 1988 ; 11: 357-427
22. Donchin E, Coles MGH. Context updating and the P300. Behavior Brain Sci. 1998 ; 21: 152-154
23. Duncan CC. Event-related brain potentials: a window on information processing in schizophrenia. Schizophr Bull. 1988 ; 14: 199-203
24. Easterbrook JA. The effect of emotion on cue utilization and the organization of behavior. Psycholog Rev. 1959 ; 66: 183-201
25. Ehlers CL, Wall TL, Chaplin RI. Long latency event-related potentials in rats: effects of dopaminergic and serotonergic depletions. Pharmacol Biochem Behavior. 1991 ; 38: 789-793
26. Ford JM. Schizophrenia: the broken P300 and beyond. Psychophysiology. 1999 ; 36: 667-682 (Pubitemid 29498325)
27. Ford JM, Pfefferbaum A, Roth W. P3 and schizophrenia. Ann NY Acad Sci. 1992 ; 658: 146-162
28. Ford JM, Mathalon DH, Marsh L, Faustman WO, Harris D, Hoff AL, et al. P300 amplitude is related to clinical state in severely and moderately ill patients with schizophrenia. Biol Psychiatry. 1999 ; 46: 94-101 (Pubitemid 29296822)
29. Ford JM, Sullivan EV, Marsh L, White PM, Lim KO, Pfefferbaum A. The relationship between P300 amplitude and regional gray matter volumes depends upon the attentional system engaged. Electroencephal Clin Neurophysiol. 1994 ; 90: 214-228 (Pubitemid 24090794)
30. FoxJ (2009) CAR: companion to applied regressionAvailable at: http://CRAN.R-project.org/package=car.
31. Friedman D, Cycowicz YM, Gaeta H. The novelty P3: an event-related brain potential (ERP) sign of the brain's evaluation of novelty. Neurosci Biobehavior Rev. 2001 ; 25: 355-373 (Pubitemid 32624376)
32. Frodl T, Meisenzahl EM, Müller D, Greiner J, Juckel G, Leinsinger G, et al. Corpus callosum and P300 in schizophrenia. Schizophr Res. 2001 ; 49: 107-119 (Pubitemid 32434318)
33. Frommann I, Brinkmeyer J, Ruhrmann S, Hack E, Brockhaus-Dumke A, Bechdolf A, et al. Auditory P300 in individuals clinically at risk for psychosis. Int J Psychophysiol. 2008 ; 70: 192-205
34. Gallinat J, Riedel M, Juckel G, Sokullu S, Frodl T, Moukhtieva R, et al. P300 and symptom improvement in schizophrenia. Psychopharmacology. 2001 ; 158: 55-65
35. Glover A, Ghilardi M, Bodis-Wollner I, Onofrj M. Alterations in event-related potentials (ERPs) of MPTP-treated monkeys. Electroencephal Clinl Neurophysiol (Evoked Potentials Section). 1988 ; 71: 461-468
36. Goldsmith SK, Joyce JN. Dopamine D2 receptors are organized in bands in normal human temporal cortex. Neuroscience. 1996 ; 74: 435-451 (Pubitemid 26274214)
37. Gonul AS, Suer C, Coburn K, Ozesmi Ç, Oguz A, Yilmaz A. Effects of olanzapine on auditory P300 in schizophrenia. Progr Neuro-Psychopharmacol Biol Psychiatry. 2003 ; 27: 173-177 (Pubitemid 36126660)
38. Halliday R, Naylor H, Brandeis D, Callaway E, Yano L, Herzig K. The effect of D-amphetamine, clonidine, and yohimbine on human information processing. Psychophysiology. 1994 ; 31: 331-337 (Pubitemid 24189734)
39. Hill SY, Locke J, Zezza N, Kaplan B, Neiswanger K, Steinhauer SR, et al. Genetic association between reduced P300 amplitude and the DRD2 dopamine receptor A1 allele in children at high risk for alcoholism. Biol Psychiatry. 1998 ; 43: 40-51 (Pubitemid 28059071)
40. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979 ; 6: 65-70
41. Jeon Y, Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology. 2003 ; 40: 684-701 (Pubitemid 37128034)
42. Kirihara K, Araki T, Kasai K, Maeda K, Hata A, Uetsuki M, et al. Confirmation of a relationship between reduced auditory P300 amplitude and thought disorder in schizophrenia. Schizophr Res. 2005 ; 80: 197-201 (Pubitemid 41713645)
43. Klorman R. Cognitive event-related potentials in attention deficit disorder. J Learn Disabil. 1991 ; 24: 130-140
44. Knight RT. Decreased response to novel stimuli after prefrontal lesions in man. Electroencephalography and Clinical Neurophysiology/Evoked Potentials Section. 1984 ; 59: 9-20 (Pubitemid 14128147)
45. Knight RT. Contribution of human hippocampal region to novelty detection. Nature. 1996 ; 383: 256-259 (Pubitemid 26317674)
46. Kok A. On the utility of P3 amplitude as a measure of processing capacity. Psychophysiology. 2001 ; 38: 557-577 (Pubitemid 32422300)
47. Korostenskaja M, Dapsys K, Siurkute A, Maciulis V, Ruksenas O, Kähkönen S. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders. Progr Neuro- Psychopharmacol Biol Psychiatry. 2005 ; 29: 543-548 (Pubitemid 40603829)
48. Kramer UM, Cunillera T, Camara E, Marco-Pallares J, Cucurell D, Nager W, et al. The impact of catechol-o-methyltransferase and dopamine D4 receptor genotypes on neurophysiological markers of performance monitoring. J Neurosci. 2007 ; 27: 14190-14198 (Pubitemid 351377871)
49. Lidow MS, Goldman-Rakic PS, Rakic P, Innis RB. Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. Proc Natl Acad Sci USA. 1989 ; 86: 6412-6416 (Pubitemid 19210661)
50. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 1987 ; 91: 415-433 (Pubitemid 17038204)
51. Linden DEJ. The P300: where in the Brain is it produced and what does it tell us?. Neuroscientist. 2005 ; 11: 563-576 (Pubitemid 41611868)
52. Liu J, Kiehl KA, Pearlson G, Perrone-Bizzozero NI, Eichele T, Calhoun VD. Genetic determinants of target and novelty-related event-related potentials in the auditory oddball response. NeuroImage. 2009 ; 46: 809-816
53. Mathalon DH, Ford JM, Pfefferbaum A. Trait and state aspects of p300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry. 2000 ; 47: 434-449 (Pubitemid 30110615)
54. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. NeuroImage. 2000 ; 12: 268-275
55. McCarley RW, Shenton ME, O'Donnell BF, Faux SF, Kikinis R, Nestor PG, et al. Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia. Arch Gen Psychiatry. 1993 ; 50: 190-197 (Pubitemid 23077473)
56. McCormick T, McNeel T. Acute psychosis and Ritalin abuse. Texas State J Med. 1963 ; 59: 99-100
57. Michie PT, Innes-Brown H, Todd J, Jablensky AV. Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders. Biol Psychiatry. 2002 ; 52: 749-758
58. Mills KC, Spruill SE, Kanne RW, Parkman KM, Zhang Y. The influence of stimulants, sedatives, and fatigue on tunnel vision: risk factors for driving and piloting. Human Factors. 2001 ; 43: 310-327 (Pubitemid 32906171)
59. Mintzer J, Targum SD. Psychosis in elderly patients: classification and pharmacotherapy. J Geriatr Psychiatry Neurol. 2003 ; 16: 199-206 (Pubitemid 37464225)
60. Mulert C, Juckel G, Giegling I, Pogarell O, Leicht G, Karch S, et al. A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. Neuropsychopharmacology. 2006 ; 31: 1335-1344 (Pubitemid 43971850)
61. Murai T, Yoshida Y, Koide S, Takada K, Misaki T, Koshikawa N, et al. Clonidine reduces dopamine and increases GABA in the nucleus accumbens: an in vivo microdialysis study. Pharmacol Biochem Behavior. 1998 ; 60: 695-701 (Pubitemid 28341930)
62. Newman-Tancredi A, Audinot-Bouchez V, Gobert A, Millan MJ. Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. Eur J Pharmacol. 1997 ; 319: 379-383 (Pubitemid 27056063)
63. Nieuwenhuis S, Aston-Jones G, Cohen JD. Decision making, the P3, and the locus coeruleus-norepinephrine system. Psychol Bull. 2005 ; 131: 510-532 (Pubitemid 41168494)
64. Nishimura N, Ogura C, Ohta I. Effects of the dopamine-related drug bromocriptine on event-related potentials and its relation to the law of initial value. Psychiatry Clin Neurosci. 1995 ; 49: 79-86
65. O'Donnell BF, Vohs JL, Hetrick WP, Carroll CA, Shekhar A. Auditory event-related potential abnormalities in bipolar disorder and schizophrenia. Int J Psychophysiol. 2004 ; 53: 45-55 (Pubitemid 38686681)
66. Okubo Y, Olsson H, Ito H, Lofti M, Suhara T, Halldin C, et al. PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. NeuroImage. 1999 ; 10: 666-674 (Pubitemid 30026760)
67. Oranje B, Gispen-de Wied CC, Westenberg HGM, Kemner C, Verbaten MN, Kahn RS. No effects of L-DOPA and bromocriptine on psychophysiological parameters of human selective attention. J Psychopharmacol. 2006 ; 20: 789-798 (Pubitemid 44622743)
68. Otten LJ, Gaillard AW, Wientjes CJ. The relation between event-related brain potential, heart rate, and blood pressure responses in an S1-S2 paradigm. Biol Psychol. 1995 ; 39: 81-102
69. Pfefferbaum A, Ford JM, White PM, Mathalon D. Event-related potentials in alcoholic men: P3 amplitude reflects family history but not alcohol consumption. Alcohol: Clin Exper Res. 1991 ; 15: 839-850
70. Pfefferbaum A, Ford JM, White PM, Roth WT. P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms. Arch Gen Psychiatry. 1989 ; 46: 1035-1044 (Pubitemid 19278233)
71. Pineda JA, Foote SL, Neville HJ. Effects of locus coeruleus lesions on auditory, long-latency, event- related potentials in monkey. J Neurosci. 1989 ; 9: 81-93 (Pubitemid 19057176)
72. Pineda JA, Swick D. Visual P3-like potentials in squirrel monkey: effects of a noradrenergic agonist. Brain Res Bull. 1992 ; 28: 485-491
73. PinheiroJBatesDDebRoySSarkarDR Core Team (2009) NLME: Linear and nonlinear mixed effects models. Available at: http://CRAN.R-project.org/package= nlme
74. Polich J. Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol. 2007 ; 118: 2128-2148 (Pubitemid 47385341)
75. Polich J, Kok A. Cognitive and biological determinants of P300: an integrative review. Biol Psychol. 1995 ; 41: 103-146
76. Polich J, Ladish C, Bloom FE. P300 assessment of early Alzheimer's disease. Electroencephal Clin Neurophysiol (Evoked Potentials Section). 1990 ; 77: 179-189 (Pubitemid 20158462)
77. Post R. Cocaine psychoses: a continuum model. Am J Psychiatry. 1975 ; 132: 225-231
78. Ratsma JE, Stelt O, Schoffelmeer ANM, Westerveld A, Gunning WB. P3 event-related potential, dopamine D2 receptor A1 allele, and sensation-seeking in adult children of alcoholics. Alcohol: Clin Exper Res. 2001 ; 25: 960-967 (Pubitemid 32656110)
79. R Development Core Team (2009) R: a language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org.
80. Robbins TW. Relationship between reward-enhancing and stereotypical effects of psychomotor stimulant drugs. Nature. 1976 ; 264: 57-59
81. Rosenfeld JP, Johnson MM, Koo J. Ongoing ischemic pain as a workload indexed by P3 amplitude and latency in real-versus feigned-pain conditions. Psychophysiology. 1993 ; 30: 253-260 (Pubitemid 23108335)
82. Ruggieri S, Stocchi F, Carta A, Agnoli A. Side effects of subcutaneous apomorphine in Parkinson's patients. Lancet. 1989 ; 1: 566 (Pubitemid 19075251)
83. Salisbury DF, Shenton ME, Sherwood AR, Fischer IA, Yurgelun-Todd DA, Tohen M, et al. First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe. Arch Gen Psychiatry. 1998 ; 55: 173-180 (Pubitemid 28087604)
84. Schall U, Catts SV, Karayanidis F, Ward PB. Auditory event-related potential indices of fronto-temporal information processing in schizophrenia syndromes: valid outcome prediction of clozapine therapy in a three-year follow-up. Int J Neuropsychopharmacol. 1999 ; 2: 83-93
85. Schatzberg AF. Employing pharmacologic treatment of bipolar disorder to greatest effect. J Clin Psychiatry. 2004 ; 65 (Suppl 15). 15-20
86. Stanzione P, Fattapposta F, Giunti P, D'Alessio C, Tagliati M, Affricano C, et al. P300 variations in parkinsonian patients before and during dopaminergic monotherapy: a suggested dopamine component in P300. Electroencephal Clin Neurophysiol (Evoked Potentials Section). 1991 ; 80: 446-453
87. Steiger MJ, Quinn NP, Marsen CD. The clinical use of apomorphine in Parkinson's disease. J Neurol. 1992 ; 239: 389-393
88. Swick D, Pineda JA, Foote SL. Effects of systemic clonidine on auditory event-related potentials in squirrel monkeys. Brain Res Bull. 1994 ; 33: 79-86 (Pubitemid 124010115)
89. Takeshita S, Ogura C. Effect of the dopamine D2 antagonist sulpiride on event-related potentials and its relation to the law of initial value. Int J Psychophysiol. 1994 ; 16: 99-106
90. Tupala E, Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Progr Neuro-Psychopharmacol Biol Psychiatry. 2004 ; 28: 1221-1247 (Pubitemid 39592920)
91. Turetsky B, Colbath EA, Gur RE. P300 subcomponent abnormalities in schizophrenia: II. Longitudinal stability and relationship to symptom change. Biol Psychiatry. 1998 ; 43: 31-39 (Pubitemid 28059070)
92. Vogel CIG, Laucht M, Furtado EF, Becker K, Schmidt MH. Association of DRD4 exon III polymorphism with auditory P300 amplitude in 8-year-old children. J Neural Transmssion. 2006 ; 113: 1935-1941 (Pubitemid 44749636)
93. Wang J, Hirayasu Y, Hokama H, Tanaka S, Kondo T, Zhang M, et al. Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia. Psychiatry Clin Neurosci. 2005 ; 59: 209-214 (Pubitemid 40524959)
94. Waters F, Price GW, Dragovic M, Jablensky A. Electrophysiological brain activity and antisaccade performance in schizophrenia patients with irst-rank (passivity) symptoms. Psychiatry Res. 2008 ; 170: 140-149
95. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine Dl receptors in prefrontal cortex. Nature. 1995 ; 376: 572-575
96. Williams G, Castner S. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience. 2006 ; 139: 263-276
97. Young ES, Perros P, Price GW, Sadler T. Acute challenge ERP as a prognostic of stimulant therapy outcome in attention-deficit hyperactivity disorder. Biol Psychiatry. 1995 ; 37: 25-33